The Technical Analyst
Cymabay Therapeutics Inc [CBAY]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cymabay Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.00% $32.48
America/New_York / 21 mar 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 728.22 mill |
| EPS: | -0.990 |
| P/E: | -32.81 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 114.79 mill |
| Avg Daily Volume: | 4.16 mill |
| RATING 2024-03-21 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -32.81 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -5.58x |
| Company: PE -32.81 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$4.85 (-85.07%) $-27.63 |
| Date: 2024-03-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 31.92 - 33.04 ( +/- 1.74%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-22 | Loewy Caroline M | Sell | 30 000 | Employee Stock Option (right to buy) |
| 2024-03-22 | Loewy Caroline M | Sell | 15 000 | Employee Stock Option (right to buy) |
| 2024-03-22 | Loewy Caroline M | Sell | 7 500 | Employee Stock Option (right to buy) |
| 2024-03-22 | Loewy Caroline M | Sell | 16 000 | Employee Stock Option (right to buy) |
| 2024-03-22 | Loewy Caroline M | Sell | 27 705 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| -97.48 |
| Last 100 transactions |
| Buy: 127 470 | Sell: 9 848 383 |
Forecast:
16:00 - $32.48
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $32.48
Forecast 2: 16:00 - $32.48
Forecast 3: 16:00 - $32.48
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $32.48 (0.00% ) |
| Volume | 0 mill |
| Avg. Vol. | 4.16 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CBAY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $24.86 | N/A | Active |
|---|
CBAY
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Latest Press Releases
2024-03-22 09:18:00 - Press Release
Gilead Sciences Announces Completion Of Acquisition Of Cymabay
Foster city, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) today announced the completion of the previously announced transaction to acquire cymabay therapeutics, inc. (nasdaq: cbay) for approximately $4.3 billion in total equity value. the addition of cymabay's investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (pbc) including pruritus, complements gilead's existing liver portfolio and aligns with its long-standing commitment to.
2024-03-04 08:00:00 - Press Release
Cymabay Announces European Medicines Agency Accepts For Review The Marketing Authorization Application For Seladelpar For The Treatment Of Primary Biliary Cholangitis
Maa validation follows recent applications for seladelpar to the u.k. mhra and u.s. fda maa validation follows recent applications for seladelpar to the u.k. mhra and u.s. fda
2024-02-28 16:45:00 - Press Release
Cymabay Reports Fourth Quarter And Year Ended December 31, 2023 Financial Results And Provides Corporate Update
Gilead sciences, inc. has proposed to acquire cymabay for $32.50 per share in cash or a total equity value of $4.3 billion.
2024-02-21 17:43:00 - Press Release
The New England Journal Of Medicine Publishes Positive Phase 3 Response Data Of Cymabay's Seladelpar In Primary Biliary Cholangitis
- seladelpar demonstrated normalization of liver biomarkers and significant reductions across three measures of patient-reported itch vs. placebo - newark, calif.
2024-02-20 16:05:00 - Press Release
Cymabay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Newark, calif., feb. 20, 2024 (globe newswire) -- cymabay therapeutics, inc. (nasdaq: cbay), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to three employees on february 16, 2024 (the “grant date”) in connection with the employees' commencement of employment at cymabay. the compensation committee of the board of directors of cymbay approved the grant of non-qualified stock options to purchase an aggregate of 99,000 shares of cymabay common stock as inducements material to the employees entering into employment with cymabay in accordance with nasdaq listing rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grants.
Latest News
2024-02-28 19:11:05 - Zacks Investment Research
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
CymaBay Therapeutics Inc. (CBAY) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.30 per share a year ago.
2024-02-12 13:55:54 - Investopedia
Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion
Shares of CymaBay Therapeutics (CBAY) soared to an all-time high Monday after Gilead Sciences (GILD) announced it's buying the developer of medicine for liver and other chronic diseases for $4.3 billion.
2024-02-12 11:09:33 - InvestorPlace
Why is CymaBay (CBAY) Stock Up 25% Today?
CymaBay (NASDAQ: CBAY ) stock is rising higher on Monday after the clinical-stage biopharmaceutical company announced an acquisition agreement with Gilead Sciences (NASDAQ: GILD ). That deal has Gilead Sciences agreeing to acquire CymaBay for $4.3 billion.
2024-02-12 09:33:50 - Invezz
Gilead to buy CymaBay Therapeutics for $4.3 billion
CymaBay Therapeutics Inc (NASDAQ: CBAY) opened more than 25% up this morning after Gilead Sciences Inc (NASDAQ: GILD) said it will buy the biopharmaceutical company for $4.3 billion. Details of Gilead-CymaBay agreement The said deal values CymaBay at $32.50 per share.
2024-02-12 08:42:43 - Reuters
Drugmaker Gilead to acquire CymaBay for $4.3 bln
Gilead Sciences on Monday said it will acquire CymaBay Therapeutics for $4.3 billion, to expand its portfolio of liver disease drugs.
2024-02-12 08:42:00 - Market Watch
Gilead strikes deal to acquire CymaBay for $4.3 billion
Gilead Sciences Inc. GILD, -0.18% said Monday it has reached a deal to acquire CymaBay Therapeutics Inc. CBAY, +2.92% for $32.50 per share in cash, a 27% premium to CymaBay's closing price Friday, for a total deal equity value of $4.3 billion. CymaBay's lead asset is seladelpar, an investigational treatment for primary biliary cholangitis, a type of liver disease that causes bile-duct damage.
2024-01-02 08:00:00 - GlobeNewsWire
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
NEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that its President and Chief Executive Officer, Sujal Shah, will present at the upcoming 42nd Annual JP Morgan Healthcare Conference taking place January 8 -11 in San Francisco, California.
2023-11-06 08:00:00 - GlobeNewsWire
CymaBay Therapeutics to Present at Upcoming Investment Conferences
NEWARK, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the UBS Biopharma Conference, November 8-9t h in Miami Beach, FL, the Piper Sandler 35th Annual Healthcare Conference, November 28-30th, in New York, NY, and the Evercore ISI 6th Annual HealthCONx Conference, November 28-30th, in Miami, Florida.
2023-10-31 16:05:00 - GlobeNewsWire
CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023
NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that it will host a conference call and live audio webcast on Tuesday, November 7, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2023 and to provide a business update.
2023-10-25 10:34:51 - Zacks Investment Research
CymaBay Therapeutics Inc. (CBAY) is on the Move, Here's Why the Trend Could be Sustainable
CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.